Claus Garbe
Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single institutional cohort study.
Wagner N, Knierim S, Luttermann F, Metzler G, Yazdi A, Bauer J, Gassenmaier M, Forschner A, Leiter U, Amaral T, Garbe C, Eigentler T, Forchhammer S, Flatz L. Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single institutional cohort study. J Am Acad Dermatol 2023
Dec 1, 2023Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single institutional cohort study.
Dec 1, 2023J Am Acad Dermatol 2023
Wagner Nikolaus, Knierim Sarah M, Luttermann Felix, Metzler Gisela, Yazdi Amir Sadegh, Bauer Jürgen, Gassenmaier Maximilian, Forschner Andrea, Leiter Ulrike, Amaral Teresa, Garbe Claus, Eigentler Thomas Kurt, Forchhammer Stephan, Flatz Lukas
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Wagner N, Lenders M, Kühl K, Reinhardt L, Fuchß M, Ring N, Stäger R, Zellweger C, Ebel C, Kimeswenger S, Oellinger A, Amaral T, Forschner A, Leiter U, Klumpp B, Hoetzenecker W, Terheyden P, Mangana J, Loquai C, Cozzio A, Garbe C, Meier F, Eigentler T, Flatz L. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy. Eur J Cancer 2023; 196:113425.
Nov 21, 2023Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Nov 21, 2023Eur J Cancer 2023; 196:113425
Wagner Nikolaus, Lenders Max M, Kühl Kathrin, Reinhardt Lydia, Fuchß Milena, Ring Natalie, Stäger Ramon, Zellweger Caroline, Ebel Chiara, Kimeswenger Susanne, Oellinger Angela, Amaral Teresa, Forschner Andrea, Leiter Ulrike, Klumpp Bernhard, Hoetzenecker Wolfram, Terheyden Patrick, Mangana Joanna, Loquai Carmen, Cozzio Antonio, Garbe Claus, Meier Friedegund, Eigentler Thomas Kurt, Flatz Lukas
EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.
Amaral T, Pop O, Chatziioannou E, Sinnberg T, Niessner H, Zhao J, Ring S, Jörger M, Schroeder C, Armeanu-Ebinger S, Cozzio A, Leiter U, Thomas I, Jochum W, Garbe C, Forchhammer S, Levesque M, Mangana J, Hölzel M, Dummer R, Schürch C, Forschner A, Flatz L. EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy. J Am Acad Dermatol 2023; 89:1072-1074.
Jul 22, 2023EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.
Jul 22, 2023J Am Acad Dermatol 2023; 89:1072-1074
Amaral Teresa, Pop Oltin Tiberiu, Chatziioannou Eftychia, Sinnberg Tobias, Niessner Heike, Zhao Jing Hua, Ring Sandra Stephanie, Jörger Markus, Schroeder Christopher, Armeanu-Ebinger Sorin, Cozzio Antonio, Leiter Ulrike, Thomas Ioannis, Jochum Wolfram, Garbe Claus, Forchhammer Stephan, Levesque Mitchell Paul, Mangana Joanna, Hölzel Michael, Dummer Reinhard, Schürch Christian M, Forschner Andrea, Flatz Lukas
Histopathologic abundance of pigmentation correlates with disease-specific survival in malignant melanoma but is not independent of current AJCC pT stage.
Aebischer V, Abu-Ghazaleh A, Metzler G, Riedl L, Garbe C, Flatz L, Eigentler T, Forchhammer S. Histopathologic abundance of pigmentation correlates with disease-specific survival in malignant melanoma but is not independent of current AJCC pT stage. Pigment Cell Melanoma Res 2023; 36:512-521.
Jul 20, 2023Histopathologic abundance of pigmentation correlates with disease-specific survival in malignant melanoma but is not independent of current AJCC pT stage.
Jul 20, 2023Pigment Cell Melanoma Res 2023; 36:512-521
Aebischer Valentin, Abu-Ghazaleh Amar, Metzler Gisela, Riedl Lena, Garbe Claus, Flatz Lukas, Eigentler Thomas Kurt, Forchhammer Stephan
Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.
Chatziioannou E, Roßner J, Aung T, Rimm D, Niessner H, Keim U, Serna-Higuita L, Bonzheim I, Kuhn Cuellar L, Westphal D, Steininger J, Meier F, Pop O, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases. EBioMedicine 2023; 93:104644.
Jun 7, 2023Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.
Jun 7, 2023EBioMedicine 2023; 93:104644
Chatziioannou Eftychia, Roßner Jana, Aung Thazin New, Rimm David L, Niessner Heike, Keim Ulrike, Serna-Higuita Lina María, Bonzheim Irina, Kuhn Cuellar Luis, Westphal Dana, Steininger Julian, Meier Friedegund, Pop Oltin Tiberiu, Forchhammer Stephan, Flatz Lukas, Eigentler Thomas Kurt, Garbe Claus, Röcken Martin, Amaral Teresa, Sinnberg Tobias
Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.
Gaissler A, Bochem J, Spreuer J, Ottmann S, Martens A, Amaral T, Wagner N, Claassen M, Meier F, Terheyden P, Garbe C, Eigentler T, Weide B, Pawelec G, Wistuba-Hamprecht K. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma. J Immunother Cancer 2023; 11
Jun 1, 2023Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.
Jun 1, 2023J Immunother Cancer 2023; 11
Gaissler Andrea, Bochem Jonas, Spreuer Janine, Ottmann Shannon, Martens Alexander, Amaral Teresa, Wagner Nikolaus, Claassen Manfred, Meier Friedegund, Terheyden Patrick, Garbe Claus, Eigentler Thomas Kurt, Weide Benjamin, Pawelec Graham, Wistuba-Hamprecht Kilian
Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.
Gaissler A, Meldgaard T, Heeke C, Babaei S, Tvingsholm S, Bochem J, Spreuer J, Amaral T, Wagner N, Klein R, Meier F, Garbe C, Eigentler T, Pawelec G, Claassen M, Weide B, Hadrup S, Wistuba-Hamprecht K. Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade. Front Immunol 2022; 13:906352.
Jul 7, 2022Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.
Jul 7, 2022Front Immunol 2022; 13:906352
Gaissler Andrea, Meldgaard Trine Sundebo, Heeke Christina, Babaei Sepideh, Tvingsholm Siri Amanda, Bochem Jonas, Spreuer Janine, Amaral Teresa, Wagner Nikolaus, Klein Reinhild, Meier Friedegund, Garbe Claus, Eigentler Thomas K, Pawelec Graham, Claassen Manfred, Weide Benjamin, Hadrup Sine Reker, Wistuba-Hamprecht Kilian
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
Garbe C, Keim U, Amaral T, Berking C, Eigentler T, Flatz L, Gesierich A, Leiter U, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zimmer L, Zouboulis C, Ascierto P, Eggermont A, Grob J, Hauschild A, Sekulovic L, Long G, Luke J, Michielin O, Peris K, Schadendorf D, Kirkwood J, Lorigan P, Central Malignant Melanoma Registry (CMMR). Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. J Clin Oncol 2022; 40:3741-3749.
Jun 16, 2022Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
Jun 16, 2022J Clin Oncol 2022; 40:3741-3749
Garbe Claus, Keim Ulrike, Amaral Teresa, Berking Carola, Eigentler Thomas Kurt, Flatz Lukas, Gesierich Anja, Leiter Ulrike, Stadler Rudolf, Sunderkötter Cord, Tüting Thomas, Utikal Jochen, Wollina Uwe, Zimmer Lisa, Zouboulis Christos C, Ascierto Paolo Antonio, Eggermont Alexander M M, Grob Jean-Jacques, Hauschild Axel, Sekulovic Lidija Kandolf, Long Georgina V, Luke Jason J, Michielin Olivier, Peris Ketty, Schadendorf Dirk, Kirkwood John M, Lorigan Paul C, Central Malignant Melanoma Registry (CMMR)
TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.
Eckardt J, Schroeder C, Martus P, Armeanu-Ebinger S, Kelemen O, Gschwind A, Bonzheim I, Eigentler T, Amaral T, Ossowski S, Riess O, Flatz L, Garbe C, Forschner A. TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. J Cancer Res Clin Oncol 2022; 149:833-840.
Feb 22, 2022TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.
Feb 22, 2022J Cancer Res Clin Oncol 2022; 149:833-840
Eckardt Julia, Schroeder Christopher, Martus Peter, Armeanu-Ebinger Sorin, Kelemen Olga, Gschwind Axel, Bonzheim Irina, Eigentler Thomas Kurt, Amaral Teresa, Ossowski Stephan, Riess Olaf, Flatz Lukas, Garbe Claus, Forschner Andrea
Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
Serna-Higuita L, Eigentler T, Garbe C, Thomas I, Seeber O, Flatz L, Leiter U, Forschner A, Amaral T, Martus P. Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. Cancers (Basel) 2021; 13
Dec 6, 2021Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
Dec 6, 2021Cancers (Basel) 2021; 13
Serna-Higuita Lina María, Eigentler Thomas Kurt, Garbe Claus, Thomas Ioannis, Seeber Olivia, Flatz Lukas, Leiter Ulrike, Forschner Andrea, Amaral Teresa, Martus Peter
Cutaneous melanoma attributable to UVR exposure in Denmark and Germany
Keim U, Gandini S, Amaral T, Katalinic A, Holleczek B, Flatz L, Leiter U, Whiteman D, Garbe C. Cutaneous melanoma attributable to UVR exposure in Denmark and Germany. Eur J Cancer 2021; 159:98-104.
Nov 3, 2021Cutaneous melanoma attributable to UVR exposure in Denmark and Germany
Nov 3, 2021Eur J Cancer 2021; 159:98-104
Keim Ulrike, Gandini Sara, Amaral Teresa, Katalinic Alexander, Holleczek Bernd, Flatz Lukas, Leiter Ulrike, Whiteman David, Garbe Claus
Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas
Gassenmaier M, Hahn M, Metzler G, Bauer J, Yazdi A, Keim U, Garbe C, Wagner N, Forchhammer S. Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas. Cancers (Basel) 2021; 13
Jul 31, 2021Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas
Jul 31, 2021Cancers (Basel) 2021; 13
Gassenmaier Maximilian, Hahn Matthias, Metzler Gisela, Bauer Jürgen, Yazdi Amir Sadegh, Keim Ulrike, Garbe Claus, Wagner Nikolaus, Forchhammer Stephan
Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036
Garbe C, Leiter U, Flatz L, Martus P, Hollezcek B, Katalinic A, Amaral T, Gandini S, Keim U, Whiteman D. Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036. Eur J Cancer 2021; 152:18-25.
May 29, 2021Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036
May 29, 2021Eur J Cancer 2021; 152:18-25
Garbe Claus, Leiter Ulrike, Flatz Lukas, Martus Peter, Hollezcek Bernd, Katalinic Alexander, Amaral Teresa, Gandini Sara, Keim Ulrike, Whiteman David
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
Gassenmaier M, Lenders M, Forschner A, Leiter U, Weide B, Garbe C, Eigentler T, Wagner N. Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors. Target Oncol 2021; 16:197-205.
Feb 8, 2021Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
Feb 8, 2021Target Oncol 2021; 16:197-205
Gassenmaier Maximilian, Lenders Max M, Forschner Andrea, Leiter Ulrike, Weide Benjamin, Garbe Claus, Eigentler Thomas K, Wagner Nikolaus
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
Wagner N, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen V, Gebhardt C, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Gassenmaier M, Weide B, Leiter U, Lenders M, Kühl K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer S, Kimeswenger S, Oellinger A, Forschner A, Eigentler T. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. J Immunother Cancer 2021; 9
Jan 1, 2021Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
Jan 1, 2021J Immunother Cancer 2021; 9
Wagner Nikolaus, Schraag Amadeus, Klumpp Bernhard, Hoetzenecker Wolfram, Berking Carola, Richtig Erika, Ziemer Mirjana, Mangana Johanna, Terheyden Patrick, Loquai Carmen, Nguyen Van Anh, Gebhardt Christoffer, Meier Friedegund, Diem Stefan, Cozzio Antonio, Flatz Lukas, Röcken Martin, Garbe Claus, Gassenmaier Maximilian, Weide Benjamin, Leiter Ulrike, Lenders Max M, Kühl Kathrin, Reinhardt Lydia, André Fiona, Dudda Milena, Ring Natalie, Ebel Chiara, Stäger Ramon, Zellweger Caroline, Lang Roland, Paar Michael, Gussek Philipp, Richtig Georg, Stürmer Suzan H, Kimeswenger Susanne, Oellinger Angela, Forschner Andrea, Eigentler Thomas K
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
Bochem J, Meier F, Terheyden P, Königsrainer A, Garbe C, Flatz L, Pawelec G, Eigentler T, Löffler M, Weide B, Niessner H, Sinnberg T, Zelba H, Spreuer J, Amaral T, Gaissler A, Pop O, Thiel K, Yurttas C, Soffel D, Forchhammer S, Wistuba-Hamprecht K. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. J Immunother Cancer 2021; 9
Jan 1, 2021Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
Jan 1, 2021J Immunother Cancer 2021; 9
Bochem Jonas, Meier Friedegund, Terheyden Patrick, Königsrainer Alfred, Garbe Claus, Flatz Lukas, Pawelec Graham, Eigentler Thomas K, Löffler Markus W, Weide Benjamin, Niessner Heike, Sinnberg Tobias, Zelba Henning, Spreuer Janine, Amaral Teresa, Gaissler Andrea, Pop Oltin, Thiel Karolin, Yurttas Can, Soffel Daniel, Forchhammer Stephan, Wistuba-Hamprecht Kilian
Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors
Winter J, Eigentler T, Garbe C, Röcken M, Cozzio A, Flatz L, Purde M, Weide B, Leiter U, Forschner A, Gassenmaier M, Lenders M, Wagner N. Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. Cancer Immunol Immunother 2020; 70:1089-1099.
Oct 28, 2020Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors
Oct 28, 2020Cancer Immunol Immunother 2020; 70:1089-1099
Winter Johanna, Eigentler Thomas K, Garbe Claus, Röcken Martin, Cozzio Antonio, Flatz Lukas, Purde Mette-Triin, Weide Benjamin, Leiter Ulrike, Forschner Andrea, Gassenmaier Maximilian, Lenders Max M, Wagner Nikolaus
Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors
Gassenmaier M, Garbe C, Schaller M, Wagner N, Bösmüller H, Niessner H, Sinnberg T, Kosnopfel C, Ikenberg K, Eigentler T, Fehrenbacher B, Rentschler M, Röcken M. Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors. Am J Pathol 2020; 190:2155-2164.
Jul 15, 2020Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors
Jul 15, 2020Am J Pathol 2020; 190:2155-2164
Gassenmaier Maximilian, Garbe Claus, Schaller Martin, Wagner Nikolaus, Bösmüller Hans, Niessner Heike, Sinnberg Tobias, Kosnopfel Corinna, Ikenberg Kristian, Eigentler Thomas K, Fehrenbacher Birgit, Rentschler Maximilian, Röcken Martin
Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy
Wagner N, Luttermann F, Gassenmaier M, Forschner A, Leiter U, Garbe C, Eigentler T. Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy. Australas J Dermatol 2020; 61:e310-e318.
Feb 12, 2020Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy
Feb 12, 2020Australas J Dermatol 2020; 61:e310-e318
Wagner Nikolaus, Luttermann Felix, Gassenmaier Maximilian, Forschner Andrea, Leiter Ulrike, Garbe Claus, Eigentler Thomas K
Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
Wagner N, Utikal J, Umansky V, Garbe C, Schadendorf D, Holland-Letz T, Herpel E, Sucker A, Lichtenberger R, Funder A, Kehrel C, Kemper C, Schuermans V, Tarnanidis K, Reith M, Gries M, Weide B, Gebhardt C. Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. J Immunother Cancer 2019; 7:343.
Dec 5, 2019Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
Dec 5, 2019J Immunother Cancer 2019; 7:343
Wagner Nikolaus, Utikal Jochen, Umansky Viktor, Garbe Claus, Schadendorf Dirk, Holland-Letz Tim, Herpel Esther, Sucker Antje, Lichtenberger Ramtin, Funder Anne, Kehrel Coretta, Kemper Charlotte, Schuermans Valerie, Tarnanidis Kathrin, Reith Maike, Gries Mirko, Weide Benjamin, Gebhardt Christoffer